Zijian Xu, M.D., Ph.D., FACC
Investigator
Dr. Zi-Jian Xu, MD, PhD, FACC, is a board-certified cardiologist and nationally recognized expert in advanced heart failure and transplant cardiology. He currently serves as Associate Director of the Cardiovascular Disease Fellowship and Medical Director of Advanced Heart Failure and Non-Invasive Cardiac Diagnostics at Sutter
Medical Center in Sacramento, California. Dr. Xu is also Chief of the Cardiology Division at Sutter Medical Group and a Clinical Professor at California Northstate University.
With over three decades of clinical, academic, and research experience, Dr. Xu has led or participated in numerous landmark clinical trials in heart failure and cardiovascular therapeutics. Trained in internal medicine and cardiology at UCLA, and in cellular and molecular physiology at Stanford University, he integrates cutting edge science with compassionate patient care.
Dr. Xu is a Fellow of the American College of Cardiology and a past president of both the Chinese American Heart Association and the Chinese American Medical Association of California. He has received multiple teaching awards and was named among Sacramento’s Best Doctors by Sacramento Magazine for several consecutive years.
Clinical trials
- Clinical trial
Heart Failure - TEAM-HF
Trial to Evaluate Safety and Effectiveness of Mechanical Circulatory Support in Patients with Advancing Heart Failure
Status: Open to Enrollment
- Clinical trial
Heart Failure COMET-HF
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients With Symptomatic Heart Failure With Severely Reduced Ejection Fraction (COMET-HF)
Status: Open to Enrollment
- Clinical trial
Heart Failure CONFIRMATION-HF
Combined Efficacy and Safety of an Early, Intensive, Management Strategy with Finerenone and SGLT2 Inhibitor in Patients Hospitalized with Heart Failure (CONFIRMATION-HF)
Status: Open to Enrollment
- Clinical trial
Heart Failure FINALITY-HF
A Randomized, Double-blind, Placebo-controlled Pragmatic Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure and Reduced Ejection Fraction Who Are Intolerant of or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)
Status: Open to Enrollment
- Clinical trial
Heart Failure REDEFINE-HF
Randomized Trial to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Heart Failure Patients With Left Ventricular Ejection Fraction Greater Than or Equal to 40% Hospitalized Due to an Episode of Acute Decompensated Heart Failure (REDEFINE-HF)
Status: Open to Enrollment